Articles with the keyword: 


The prevalence of gluten-sensitive enteropathy in iron-deficient anemia patients
sea-maid submitted, created time 1 week 1 day (www.eurekalert.org)
A research group from Iran investigated the prevalence of gluten-sensitive enteropathy (GSE) in a large group of patients with iron deficiency anemia (IDA) of obscure origin. They found that there is a high prevalence of GSE in patients with IDA of obscure origin. A gluten-free diet can improve anemia in GSE patients who have mild duodenal lesions without villous atrophy. 


Gene may open door for new sickle cell therapies
piggy submitted, created time 1 month 1 day (www.reuters.com)
U.S. researchers have discovered a gene switch that could lead to better treatments for sickle cell disease and thalassemia, two inherited blood disorders that affect millions of people, they said on Thursday.
Learning how to activate this switch might help doctors direct the body to make healthier blood cells -- in this case, replicating conditions found in the womb.
People with these blood disorders either make too little or abnormal forms of hemoglobin, the protein in red blood cells that is vital for carrying oxygen to the body's tissues 


Coordinate regulation of Fanconi anemia gene expression occurs through the Rb/E2F pathway
sea-maid submitted, created time 4 months 3 weeks (www.nature.com)
Fanconi anemia (FA) is a genome instability syndrome that is characterized by progressive bone marrow failure and a high risk of cancer. FA patients are particularly susceptible to leukemia as well as squamous cell carcinomas (SCCs) of the head and neck, anogenital region and skin. This article details experiments exploring the up and downregulation of FA. 
Danger coming with hope: Amgen's Anemia Drugs Ailing
DanyC submitted, created time 10 months 1 week (www.forbes.com)
There is a $10 billion market for drugs to treat the anemia that occurs after kidney dialysis and cancer chemotherapy. Well, a new study said Amgen and Johnson & Johnson's anti-anemia treatments raise the risk of death via blood clots, and worries coming, that these medicines actually harm patients when overused have caused doctors to limit prescriptions. 


Anemia drugs up death risk in cancer patients
sumsung submitted, created time 10 months 1 week (www.reuters.com)
Treating cancer patients with anemia drugs increases their risk of blood clots and death, U.S. researchers said on Tuesday, confirming concerns about these widely used drugs. Researchers said the drugs, including Amgen Inc's Aranesp and Johnson & Johnson's Procrit, raised the risk of death by 10 percent in patients who took them, a finding that could not be explained by the higher blood clot risk alone. 


Higher Risks: blood clots and death found for anemia anti-anemia drugs
DanyC submitted, created time 10 months 1 week (online.wsj.com)
The analysis, which is being published in this week's Journal of the American Medical Association, looked at 51 Phase III clinical studies involving Aranesp, Epogen and Procrit in patients with cancer, and comes amid a continuing safety review of the drugs by the U.S. Food and Drug Administration. Phase III studies are advanced clinical studies that are typically conducted to support FDA approval of products. 


Hematopoietic stem cell transplantation in childhood inherited bone marrow failure syndrome
davidd submitted, created time 10 months 4 weeks (www.nature.com)
Aplastic anemia is a rare disease in children that is most commonly idiopathic and less often a hereditary disorder. Hereditary bone marrow failure (BMF) syndromes, however, should be considered both in children and in adults before any attempt at treatment. In this review, they will report recent results of treatment of Fanconi anemia and other hereditary BMF syndromes. 


davidd submitted, created time 11 months 2 weeks (bloodjournal.hematologylibrary.org)
The Cooperative Study of Sickle Cell Disease reported that dactylitis, severe anemia, and leukocytosis in very young children with sickle cell disease (SCD) increased the risk of later adverse outcomes, including death, stroke, frequent pain, and recurrent acute chest syndrome. They established a prediction model of adverse outcomes in children with sickle cell anemia. The model will helps doctors choose better treatment for newborn with Sickle Cell Disease to reduce fatal rate. 
Good News:Transplants Without Tears
Eric wu submitted, created time 1 year 1 month (sciencenow.sciencemag.org)
A new treatment might allow patients to avoid some of the grueling side effects of bone marrow transplants. Researchers reported in the 23 November issue of Science that they can use a specific type of antibody to clear away old marrow stem cells in mice, allowing fresh ones to take their place. The discovery could allow patients to receive bone marrow without undergoing chemotherapy and other toxic procedures. 


Lilly clot drug works, but more bleeding seen
yangqin submitted, created time 1 year 2 months (www.reuters.com)
ORLANDO, Fla./NEW YORK - Eli Lilly and Co's investigational anti-clotting drug was better able to prevent heart attacks than the standard treatment Plavix, but the drug led to excess bleeding, a study released on Sunday found, a shortcoming that could curb its usefulness. 


New discovery leaves blood-doping athletes scratching their heads
william submitted, created time 1 year 3 months (www.eurekalert.org)
A stunning discovery may make blood doping and the treatment of severe anemia as easy as washing your hair. In the October print issue of the FASEB Journal, researchers show that hair follicles on people's head have the potential to become erythropoietin factories. EPO, the hormone responsible for the creation of red blood cells, is used illegally to enhance athletic performance and legally to treat severe anemia associated with kidney failure and chemotherapy. 


Malarial anemia: of mice and men
gh0706 submitted, created time 1 year 6 months (bloodjournal.hematologylibrary.org)
Severe malaria is manifest by a variety of clinical syndromes dependent on properties of both the host and the parasite. In young infants, severe malarial anemia (SMA) is the most common syndrome of severe disease and contributes substantially to the considerable mortality and morbidity from malaria. There is now growing evidence, from both human and mouse studies of malaria, to show that anemia is due not only to increased hemolysis of infected and clearance of uninfected red blood cells (RBCs) but also to an inability of the infected host to produce an adequate erythroid response 


A1C and Survival in Maintenance Hemodialysis Patients
amanda submitted, created time 1 year 7 months (care.diabetesjournals.org)
"In diabetic MHD patients, the apparently counterintuitive association between poor glycemic control and greater survival is explained by such confounders as malnutrition and anemia. All things equal, higher A1C is associated with increased death risk. Lower A1C levels not related to malnutrition or anemia appear to be associated with improved survival in MHD patients. " 


Identification of the FANCI Protein, a Monoubiquitinated FANCD2 Paralog Required for DNA Repair
medal submitted, created time 1 year 8 months (www.cell.com)
"Fanconi anemia (FA) is a developmental and cancer-predisposition syndrome caused by mutations in genes controlling DNA interstrand crosslink repair. Several FA proteins form a ubiquitin ligase that controls monoubiquitination of the FANCD2 protein in an ATR-dependent manner. " 


Study Urges Caution on Anemia Drug Use
daphne submitted, created time 1 year 8 months (www.examiner.com)
A flawed Medicare payment plan encourages aggressive use of a risky and costly anti-anemia drug on many kidney dialysis patients, say researchers who warn the system should be changed. A new study finds that for-profit dialysis chains give higher doses of the drug than nonprofit dialysis centers. That practice may be putting patients at risk of deadly side effects, some experts said. 